RPRX Stock Analysis: Buy, Sell, or Hold?
RPRX - Royalty Pharma plc Class A Ordinary Shares
$53.26
0.01 (0.02%)
▲
5d:
+6.1%
30d:
+9.36%
90d:
+18.88%
BUY
MODERATE Confidence
Analysis Updated: May 13, 2026 12:00 AM ET
Earnings: May 06, 2026
0d
Smart Money Distribution
RPRX is up 4.2% this week, but smart money is buying puts. Top strike: $50 2026-05-15 with 3 OI. Put ratio: 100% View Scanner →
Strength: 7.1/10
Get Alerted When RPRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RPRX shows positive signals but monitor for confirmation. Market pricing in 4.4% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: RPRX shows positive signals but monitor for confirmation. Market pricing in 4.4% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$64.84
Based on 6.8% avg growth
INTRINSIC VALUE TODAY
$40.26
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: RPRX is currently trading at $53.26, which is considered extended relative to its 30-day fair value range of $48.21 to $50.90. From a valuation perspective, the stock is trading at a premium (Forward PE: 9.5) compared to its historical average (8.3). At these levels, the market is pricing in 4.4% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, RPRX is in a strong uptrend. The price is approaching resistance at $52.16. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: RPRX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $59.25 (+11.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RPRX is in a strong uptrend. The price is approaching resistance at $52.16. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: RPRX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $59.25 (+11.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$48.21 -
$50.90
Company Quality Score
67/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
60.5%
Protect Your Profits
RPRX is technically overbought (RSI 76). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($59.25)
- NEUTRAL: Market pricing in 4.4% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$48.21 -
$50.90
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$49.11
Resistance Level
$52.16
Current Trend
Strong Uptrend
Technical data as of
May 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.49
Wall Street Target
$59.25
(+11.3%)
Revenue Growth (YoY)
11.0%
Earnings Growth (YoY)
23.2%
Profit Margin
33.9%
Valuation Premium vs History
+4.4% premium
PE vs Historical
9.5 vs 8.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.4%
(market-implied from PE analysis)
1-Year Target
$55.59
(+4%)
2-Year Target
$58.04
(+9%)
3-Year Target
$60.59
(+14%)
3-Yr Target (if PE normalizes)
(PE: 9→8)
PE COMPRESSION
$53.02
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 9.7%)
$163.35
(+207%)
Base:
(SPY PE: 9.5, Growth: 9.7%)
$70.30
(+32%)
Bear:
(PE: 8.1, Growth: 9.7%)
$59.76
(+12%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (27x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 27.18 | Current EPS (TTM): $1.90
Bull Case
$113.63
(+113%)
Analyst growth 100.0%, PE expands to 29.9
Base Case
$103.30
(+94%)
Market implied 100.0%, PE stable at 27.2
Bear Case
$35.12
(-34%)
Severe decline -20.0%, PE contracts to 23.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: May 14, 2026 11:40 AM ET
Data refreshes hourly during market hours. Next update: 12:40 PM
Data refreshes hourly during market hours. Next update: 12:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RPRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Terrance P Coyne
SELL
34791 shares
2026-04-01
Terrance P Coyne
SELL
34791 shares
2026-03-23
Terrance P Coyne
SELL
34791 shares
2026-03-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$550 | 67 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$875 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 61 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 58 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
Advanced RPRX Option Strategies
Professional options setups generated by AI based on today's RPRX price and gamma walls.
